{
    "root": "2faee58e-538b-a562-e063-6394a90add2d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin and Clavulanate Potassium",
    "value": "20250306",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "HYPROMELLOSE 2910 (15000 MPA.S)",
            "code": "288VBX44JC"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8"
        }
    ],
    "indications": "amoxicillin clavulanate potassium tablets indicated treatment infections adults pediatric patients , due susceptible isolates designated bacteria conditions listed : lower respiratory tract infections -caused beta‑lactamase‑producing isolates haemophilus influenzaeand moraxella catarrhalis . acute bacterial otitis media -caused beta‑lactamase‑producing isolates h. influenzaeand m. catarrhalis . sinusitis -caused beta‑lactamase‑producing isolates h. influenzaeand m. catarrhalis . skin skin structure infections -caused beta‑lactamase‑producing isolates staphylococcus aureus , escherichia coli , klebsiellaspecies . urinary tract infections -caused beta‑lactamase‑producing isolates e. coli , klebsiellaspecies , enterobacterspecies . limitations susceptibility test results show susceptibility amoxicillin , indicating beta-lactamase production , amoxicillin clavulanate potassium tablets used . usage reduce development drug‑resistant bacteria maintain effectiveness amoxicillin clavulanate potassium tablets antibacterial drugs , amoxicillin clavulanate potassium tablets used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
    "contraindications": "adults pediatric patients greater 40 kg : 500 mg/125 mg 875 mg/125 mg every 12 hours 250 mg/125 mg 500 mg/125 mg every 8 hours , based amoxicillin component . ( 2.2 , 2.3 ) pediatric patients aged 12 weeks ( 3 months ) older : 25 45 mg/kg/day every 12 hours 20 40 mg/kg/day every 8 hours , adult dose . ( 2.3 ) neonates infants less 12 weeks age : 30 mg/kg/day divided every 12 hours , based amoxicillin component . 125 mg/31.25 mg per 5 ml oral suspension recommended . ( 2.3 )",
    "warningsAndPrecautions": "amoxicillin clavulanate potassium tablets usp , 875 mg/125 mg white off-white , capsule shaped , film-coated tablets , debossed ‘ x ’ one side score line 3 2 side , contains 875 mg amoxicillin usp trihydrate 125 mg clavulanic acid potassium salt ( equivalent 149 mg clavulanate potassium ) . ndc : 70518-2225-00 ndc : 70518-2225-01 ndc : 70518-2225-02 ndc : 70518-2225-03 ndc : 70518-2225-04 ndc : 70518-2225-05 ndc : 70518-2225-06 ndc : 70518-2225-07 ndc : 70518-2225-08 packaging : 20 1 bottle plastic packaging : 30 1 blister pack packaging : 10 1 bottle plastic packaging : 20 1 blister pack packaging : 14 1 blister pack packaging : 30 1 blister pack packaging : 100 1 box packaging : 1 1 pouch packaging : 14 1 bottle plastic dispense tight container [ usp ] . advise patients keep closed container . inner seal intact . store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . keep reach children . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "history serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin clavulanate potassium tablets beta-lactams ( e.g . , penicillins cephalosporins ) . ( 4.1 ) history cholestatic jaundice/hepatic dysfunction associated amoxicillin clavulanate potassium tablets . ( 4.2 )",
    "indications_original": "Amoxicillin and clavulanate potassium tablets are indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:\n                  \n                     \n                        Lower Respiratory Tract Infections -caused by beta‑lactamase‑producing isolates of\n  \n   Haemophilus influenzaeand\n  \n   Moraxella catarrhalis.\n \n  \n                     \n                        Acute Bacterial Otitis Media -caused by beta‑lactamase‑producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Sinusitis -caused by beta‑lactamase‑producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Skin and Skin Structure Infections -caused by beta‑lactamase‑producing isolates of\n  \n   Staphylococcus aureus, Escherichia coli,and\n  \n   Klebsiellaspecies\n  \n   .\n                     \n                     \n                        Urinary Tract Infections -caused by beta‑lactamase‑producing isolates of\n  \n   E. coli, Klebsiellaspecies\n  \n   ,and\n  \n   Enterobacterspecies.\n \n  \n                  \n                  \n                     Limitations of Use \n   \n                     \n                       When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, amoxicillin and clavulanate potassium tablets should not be used. \n  \n                     \n                          Usage \n   \n                     \n                       To reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets and other antibacterial drugs, amoxicillin and clavulanate potassium tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "Adults and Pediatric Patients greater than 40 kg: 500 mg/125 mg or 875 mg/125 mg every 12 hours or 250 mg/125 mg or 500 mg/125 mg every 8 hours, based on amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/31.25 mg per 5 mL oral suspension is recommended. ( 2.3 )",
    "warningsAndPrecautions_original": "Amoxicillin and Clavulanate Potassium Tablets USP, 875 mg/125 mg are white to off-white, capsule shaped, film-coated tablets, debossed with ‘X’ on one side and score line in between 3 and 2 on the other side, contains 875 mg of amoxicillin USP as the trihydrate and 125 mg of clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium).\n                  NDC: 70518-2225-00\n                  NDC: 70518-2225-01\n                  NDC: 70518-2225-02\n                  NDC: 70518-2225-03\n                  NDC: 70518-2225-04\n                  NDC: 70518-2225-05\n                  NDC: 70518-2225-06\n                  NDC: 70518-2225-07\n                  NDC: 70518-2225-08\n                  PACKAGING: 20 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 10 in 1 BOTTLE PLASTIC\n                  PACKAGING: 20 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC\n                  \n                  Dispense in a tight container [see USP]. Advise patients to keep in a closed container. Use only if inner seal is intact.\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  \n                  Keep out of the reach of children.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin and clavulanate potassium tablets or to other beta-lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin and clavulanate potassium tablets. ( 4.2 )"
}